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Note
The ADAM9 gene transcript 2 isoforms of mRNA with altered splicing results the lost of exon 18 in the second isoform of ADAM9 mRNA and early stop codon.
Description
ADAM9 gene extends 108,276 base pairs with 22 exons which gives rise to 2 different ADAM9 transcripts with differential splicing. The mRNA of ADAM9 isoform 1 is 4111 base pair and isoform 2 is 4005. ADAM9 isoform 2 lacks exon 18 of iso-form 1 in the coding region, which results in a frameshift and an early stop codon. The isoform 2 lacks the c-terminal transmembrane and cyto-plasmic domains and is a secreted form.
Transcription
Isoform 1 mRNA of ADAM9 (NM_003816) has a size of 4111 bp, isoform 2 mRNA (NM_001005845) has a size of 4005 bp. ADAM9 mRNA is equally expressed in many tissue. Among cancer progression, ADAM9 mRNA is relatively highly expressed in prostate cancer and breast cancer. However, little is known of differential expression between different isoform of ADAM9.
Pseudogene
No pseudogene has reported for ADAM9.
ADAM9 gene is located on chromosome 8p11.23 spread out on 108,276 deoxynucleotides contained 22 exons. The coding sequence of ADAM9 is 2460 nucleotides. Two isoforms reported, isoform 1 of ADAM9 carried full-length membrane bond ADAM9 and isoform 2 carried soluble form of ADAM9 (sADAM9). The sADAM9 is due to alternative splicing in which lost of exon 18 and results in early stop translation in exon 19.
Protein
Note Two different isoform of ADAM9 was reported, the full length and soluble form of ADAM9. Recent report suggests promoter polymorphisms regulated ADAM9 transcription that plays a protective role against Alzheimer's disease.
Description
The predicted molecular mass of ADAM9 is about 84 KDa. ADAM9 contained coding sequence of 2460 nucleotides which encoding amino acid of 819 residues. The full length of active ADAM9 contained several functional regions including metalloproteinase, disintegrin, cystein rich, EGF-like, transmembrane and cytoplasmic domains. The pro-domain of ADAM9 was removed by furin-type convertase during ADAM9 translocated onto membrane and become active form. Recent reports indicated soluble form of ADAM9 cloned from human cDNA library that showed increased of cancer invasion in malignant progression.
Expression
ADAM9 is ubiquitously expressed. SAGE analyses of ADAM9 expression demonstrated that ADAM9 is expressed in the bone marrow, lymph node, brain, retina, heart, skin, muscle, lung, prostate, breast and placenta. Increased expression of ADAM9 was reported in several cancers, including gastric, breast, prostate, colon, and pancreatic cancers. Splicing alteration and lost of exon 18 of ADAM9 causes lost of transmembrane domain and early stop in soluble form of ADAM9.
Localisation
Full length has N-terminal signal peptide and a single hydrophobic region predicted to be transmembrane domain. Hence, the full length of ADAM9 is localized to the plasma membrane. Soluble ADAM9 lack the transmembrane domain and cytoplasmic domain and to be released out of cell.
Function
Ectodomain shedding:
Metalloproteinase domain of ADAM9 is zinc dependent. Metallo-proteinase has been showed to involve ectodomain shedding (see table below). One such protein is the heparin-binding EGFlike growth factor (HB-EGF) and amyloid precursor protein (APP). 2. Matrix Degradation: purified metalloproteinase domain of ADAM9 showed the ability to digest fibronectin, gelatin and beta-casein. Secreted form of ADAM9 showed the ability to digest laminin and promote cancer invasion. 3. Cell contact: ADAM9 specifically bind to integrin alpha 6 beta 1 , a laminin receptor, via disintegrin region of ADAM9 through non-RGD mechanism. ADAM9 also have been implicated in binding of a v beta 5 in divalent cation dependent condition, suggests ADAM9 can function as adhesion molecule for cell-cell and cellmartrix interaction. Secreted form of ADAM9 binds directly to alpha 6 beta 4 and alpha 2 beta 1 integrin and Two isoforms of ADAM9 with their specific function. Soluble form of ADAM9 has function to active APP either on the same cell or neighbor cell.
ability to cleave laminin and promote cancer progression.
Cysteine-Rich domain:
The ADAM Cysteine-rich domain is not found in other organisms, such as virus, archaeal, bacterial or plant. The function of cysteinerich domain might involved in complement the binding ability of disintegrin-mediated interactions. ADAM9 gene promoter region contained 4 polymorphisms: -542C/T, -600A/C, -963A/G and -1314T/C. 1314C showed higher ADAM9 transcription compared to 1314T.
Implicated in
Prostate cancer
Note ADAM9 has been implicated in prostate cancer progression and the production of reactive oxygen species. Large cohort of clinic evaluation demonstrated ADAM9 is upregulated in prostate cancer in both mRNA and protein level. ADAM9 protein expression can be upregulated by androgen in AR-positive but not in AR-negative prostate cancer cells that is through downstream ROS as mediator to induce ADAM9 expression. ADAM9 protein expression is associated with shortened PSA-relapse-free survival in clinic evaluation.
Pancreatic cancer
Note Pancreatic ductal adenocarcinomas showing increased of ADAM9 expression in microarray analyses and clinic evaluation that correlated with poor tumor differentiation and shorter overall survival rate. 
Breast cancer
Lung cancer
Note
The increased of ADAM9 expression in lung cancer enhanced cell adhesion and invasion of non-small cell lung cancer through change adhesion properties and sensitivity to growth factors, and increase its capacity of brain metastasis.
Renal cell carcinoma
Note ADAM9 was implicated increased expression in renal cell carcinoma and associated with tumor progression. It also showed higher of ADAM9 expression is associated with shorten patient survival rate.
Alzheimer's disease
Note
The amyloid precursor protein (APP) of Alzheimer's disease is a transmembrane protein processed via either the non-amyloidogenic or amyloidogenic pathways. In the non-amyloidogenic pathway, alpha-secretase cleaves APP within the Abeta peptide region releasing a large soluble fragment sAPPalpha that has neuroprotective properties. In the amyloidogenic pathway, beta-secretase and gamma-secretase sequentially cleave APP to generate the intact Abeta peptide, which is neurotoxic. In ADAM9 expression analyses showed increase in production of sAPPalpha upon phorbol ester treatment of cell that co-express of ADAM9 and APP. ADAM9 did not cleave at the Lys16-Leu17 bone but at the His14-Gln15 bone in the Abeta domain of APP cleave site. Hence, ADAM9 might play role in protective against sporadic Alzheimer's disease.
